HORMONAL ANTINEOPLASTICS
\hɔːmˈə͡ʊnə͡l ˌantɪnˌiːə͡ʊplˈastɪks], \hɔːmˈəʊnəl ˌantɪnˌiːəʊplˈastɪks], \h_ɔː_m_ˈəʊ_n_əl ˌa_n_t_ɪ_n_ˌiː__əʊ_p_l_ˈa_s_t_ɪ_k_s]\
Sort: Oldest first
-
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
By DataStellar Co., Ltd
Word of the day
Procollagen Proline Dioxygenase
- mixed-function oxygenase that catalyzes hydroxylation prolyl-glycyl-containing-peptide, usually in protocollagen, hydroxyprolylglycyl-peptide. The enzyme utilizes molecular oxygen with a concomitant oxidative decarboxylation of 2-oxoglutarate to succinate. EC 1.14.11.2.